Afrezza’s Underperformance Is a Cause of Concern for MannKind Corporation (MNKD)
Mannkind Corporation (NASDAQ:MNKD) is worried with respect to the performance of its inhaled insulin drug, Afrezza. The company’s drug is struggling to create a favorable impact in the diabetes market even after launching the product five months back. The company appeared to have done well in partnering with Sanofi SA (ADR) (NYSE:SNY) though it failed to translate into results. As a result, it is struggling to find out the reasons why.
It appears that the Inhaled insulin drug’s struggle in the diabetes market is nothing new. That is because even Pfizer Inc. (NYSE:PFE) seemed to have met with the same fate when it launched the product, Exubera, sometime in 2006. However, the biggest worry for Mannkind Corporation (NASDAQ:MNKD) is that Afrezza is underperforming even in comparison with the Exubera, which is considered a failure commercially. As a result, Pfizer was forced to dump the product after one year’s time.
Mannkind Corporation (NASDAQ:MNKD) is unable to accept the underperformance of its drug in comparison with Exubera. The company believes that Afrezza is much superior in every respect compared to Pfizer’s Exubera. Therefore, the developer of the drug expects the drug to succeed where Exubera struggled to find success. However, following the launch of its product nearly five months ago, the company has remained empty hand unable to digest the underperformance.
Despite Mannkind Corporation (NASDAQ:MNKD)’s positive opinion about Afrezza, its failure could suggest that Sanofi SA (ADR) (NYSE:SNY) has probably failed to have learned lessons from Pfizer Inc. (NYSE:PFE)’s experience. That might have landed it in marketing the inhaled insulin drug poorly in the diabetes market.
While GlaxoSmithKline plc (ADR) (NYSE:GSK) has been successful in marketing the prescription drug of Tanzeum, a GLP-1 injection. Though the drug is not insulin, its comparison could suggest that Sanofi has failed to market the inhaled insulin drug effectively. Its years of experience in marketing also failed to help the Afrezza succeed.
Latest posts by Viraj Shah (see all)
- Tesla Motors Inc (NASDAQ:TSLA)’s Elon Musk Is Going After Semi Truck Industry - November 17, 2017 04:37 AM PDT
- Tesla Motors Inc (NASDAQ:TSLA) Is Not “Hotbed for Racist Behavior” - November 15, 2017 06:58 AM PDT
- Nikola Tesla and Tesla Motors Inc (TSLA) – The Past & Future of the World You Cannot Ignore- Part 1 - May 15, 2017 05:11 AM PDT